Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.47 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446408 | 1.00 | MAPK1 (0.51) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL17685984 | 0.87 | MEN1 (0.44) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL4598226 | 0.87 | ROCK2 (0.50) | MEN1KMT2APHGDHDCAF1ACP3 | |
| SCHEMBL14691111 | 0.87 | PHGDH (0.50) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL14393701 | 0.85 | MAPK1 (0.47) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL29739235 | 0.85 | KCNQ3 (0.49) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL29751805 | 0.85 | MAPK1 (0.47) | MAPK1MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL22077638 | 0.84 | DCAF1 (0.43) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL14691522 | 0.84 | PHGDH (0.43) | MAPK1MEN1KMT2APHGDHDCAF1 | |
| SCHEMBL18162818 | 0.84 | ALDH1A1 (0.51) | MAPK1MEN1KMT2AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925629-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3307727-B1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | ASANA BIOSCIENCES, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842429-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | Asana BioSciences, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021086726-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | Asan BioSciences, LLC (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2020-06-11 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2016205418-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160362407-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| WO-2016100051-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885MEN1 3963/4885KMT2A 431/4885 |
| US-11925629-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885MEN1 3963/4885KMT2A 431/4885 |
| US-20160362407-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPK1 7/4885MEN1 1013/4885KMT2A 573/4885 |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | KRAS, NRAS, BRAF | MAPK1 8/4885MEN1 697/4885KMT2A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.